









Markets
/
Stocks
/
nasdaq-cai
/

Caris Life Sciences Inc

CAI

30.910USD

-0.270-0.87%

Market hours （ET）Quotes delayed by 15 min

8.69BMarket Cap

LossP/E TTM



Caris Life Sciences Inc

30.910

-0.270-0.87%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Caris Life Sciences Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Caris Life Sciences Inc's Score

Industry at a Glance

Industry Ranking

83 / 210

Overall Ranking

184 / 4616

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

39.125

Target Price

+30.68%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Caris Life Sciences Inc Highlights

StrengthsRisks

Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.

Fairly Valued

The company’s latest PE is 0.00, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 130.22M shares, increasing 49.73% quarter-over-quarter.

Held by Philippe Laffont

Star Investor Philippe Laffont holds 10.14M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 7.74, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.74

Change



Financials

9.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.27

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.73

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Caris Life Sciences Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.85, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19.

Score

Industry at a Glance

Previous score

6.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

The company’s current earnings forecast score is 9.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Caris Life Sciences Inc is 39.00, with a high of 45.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

39.125

Target Price

+30.68%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Caris Life Sciences Inc

CAI

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 7.09, which is higher than the Healthcare Equipment & Supplies industry's average of 6.77. Sideways: Currently, the stock price is trading between the resistance level at 33.58 and the support level at 28.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

0.47

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.096

Neutral

RSI(14)

50.347

Neutral

STOCH(KDJ)(9,3,3)

40.719

Buy

ATR(14)

1.915

Low Volatility

CCI(14)

-30.976

Neutral

Williams %R

52.386

Neutral

TRIX(12,20)

-0.199

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

MA10

MA20

MA50

MA100

MA200

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Halbert (David D)

122.76M

-0.12%

Sixth Street Partners, LLC

24.39M

J.H. Whitney Capital Partners, LLC

20.26M

Castleman Peter M

10.37M

+32049.87%

Coatue Management, L.L.C.

Star Investors

10.14M

Fidelity Management & Research Company LLC

8.61M

Braidwell LP

7.32M

T. Rowe Price Investment Management, Inc.

7.30M

T. Rowe Price Associates, Inc.

Star Investors

6.76M

Neuberger Berman, LLC

6.24M

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 4.59, which is higher than the Healthcare Equipment & Supplies industry's average of 4.57. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.